Delcath (DCTH) Treats First Patients in Germany with CHEMISAT Delivery System
Tweet
Share
E-mailGet Alerts DCTH Hot Sheet
Join SI Premium – FREE
Delcath Systems, Inc., (Nasdaq: DCTH) reports that the first patients in Germany have been treated with the Delcath Hepatic CHEMOSAT Delivery System at the Johann Wolfgang Goethe University Hospital, a premier European cancer treatment and research center located in Frankfurt. The cases were treated as part of the initial launch and training agreement the Company announced with the hospital in December 2011.
Two patients were treated for inoperable, liver-dominant metastases, one from cutaneous melanoma and one from breast cancer. The treating physicians reported that both patients were treated successfully without procedure-related complications.
Two patients were treated for inoperable, liver-dominant metastases, one from cutaneous melanoma and one from breast cancer. The treating physicians reported that both patients were treated successfully without procedure-related complications.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Boeing names Ryan Shedd as new SVP and controller
- Solowin Holdings marks 10 years, expands into stablecoins and AI
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
